BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos MA, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos MV, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2021;35:31-44. [PMID: 32814840 DOI: 10.1038/s41375-020-01016-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Shah MR, Gabel A, Beers S, Salaru G, Lin Y, Cooper DL. COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination. Clin Lymphoma Myeloma Leuk 2022;22:e321-6. [PMID: 34872881 DOI: 10.1016/j.clml.2021.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 2021;11:138. [PMID: 34341335 DOI: 10.1038/s41408-021-00530-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Gavriatopoulou M, Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. Br J Haematol 2021. [PMID: 34528249 DOI: 10.1111/bjh.17841] [Reference Citation Analysis]
4 Crees ZD, Stockerl-Goldstein K. COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. Am J Med 2022;135 Suppl 1:S49-52. [PMID: 35081378 DOI: 10.1016/j.amjmed.2022.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yang Y, Ding R, Wang R. Identification of candidate targets and mechanisms involved in miRNA regulation in multiple myeloma. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-021-02482-1] [Reference Citation Analysis]
6 Hoornaert E, Dachy F, Hansenne A, Bailly S, van Maanen A, Gruson D, Vekemans MC. COVID-19: impact of vaccination in myeloma patients. Ann Hematol 2022. [PMID: 35411439 DOI: 10.1007/s00277-022-04799-7] [Reference Citation Analysis]
7 Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, Pontone M, Di Martino S, Laquintana V, La Malfa A, Di Domenico EG, Di Bella O, Falzone G, Ensoli F, Vujovic B, Morrone A, Ciliberto G, Mengarelli A. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol 2021;14:81. [PMID: 34001183 DOI: 10.1186/s13045-021-01090-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
8 Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, Mccarthy PL, Munshi NC. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet Haematology 2022;9:e143-61. [DOI: 10.1016/s2352-3026(21)00283-0] [Reference Citation Analysis]
9 Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Trougakos IP, Dimopoulos MA. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Adv 2021;5:4398-405. [PMID: 34529762 DOI: 10.1182/bloodadvances.2021005444] [Reference Citation Analysis]
10 [DOI: 10.1101/2021.05.15.21256814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, Mitra AK, Bergquist T, Kavuluru R, Li X, Sharafeldin N, Su J, Topaloglu U; National COVID Cohort Collaborative Consortium. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative. J Clin Oncol 2022;:JCO2102419. [PMID: 35286152 DOI: 10.1200/JCO.21.02419] [Reference Citation Analysis]
12 Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E, Angelopoulou M, Baltadakis I, Panayiotidis P, Trougakos IP, Vassilakopoulos TP, Pagoni M, Dimopoulos MA. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers (Basel) 2021;13:4480. [PMID: 34503290 DOI: 10.3390/cancers13174480] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hemminki K, Försti A, Houlston R, Sud A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer 2021. [PMID: 34398972 DOI: 10.1002/ijc.33762] [Reference Citation Analysis]
14 Ludwig H, Meckl A, Engelhardt M. Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience. Hemasphere 2021;5:e597. [PMID: 34235399 DOI: 10.1097/HS9.0000000000000597] [Reference Citation Analysis]
15 Alkis N, Baysal M. Subacute thyroiditis after SARS-CoV-2 BNT162b2 vaccine in a multiple myeloma patient. SAGE Open Medical Case Reports 2022;10:2050313X2210913. [DOI: 10.1177/2050313x221091392] [Reference Citation Analysis]
16 Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 2022;97 Suppl 1:S3-S25. [PMID: 35234302 DOI: 10.1002/ajh.26512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ludwig H, San-Miguel J, Munshi N, Sonneveld P, Mateos MV, Moreau P, Terpos E. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol 2021;96:896-900. [PMID: 34057243 DOI: 10.1002/ajh.26263] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
18 Pozzi S, Bari A, Pecherstorfer M, Vallet S. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel) 2021;13:4978. [PMID: 34638462 DOI: 10.3390/cancers13194978] [Reference Citation Analysis]
19 Lemieux C, Muffly LS, Iberri DJ, Craig JK, Johnston LJ, Lowsky R, Shiraz P, Rezvani AR, Frank MJ, Weng WK, Meyer E, Shizuru JA, Arai S, Liedtke M, Negrin RS, Miklos DB, Sidana S. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplant 2021. [PMID: 34163014 DOI: 10.1038/s41409-021-01371-1] [Reference Citation Analysis]
20 Kesireddy M, Holstein SA. The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2032656] [Reference Citation Analysis]
21 McCaughan G, Di Ciaccio P, Ananda-Rajah M, Gilroy N, MacIntyre R, Teh B, Weinkove R, Curnow J, Szer J, Enjeti AK, Ross DM, Mulligan S, Trotman J, Dickinson M, Quach H, Choi P, Polizzotto MN, Tam CS, Ho PJ, Ku M, Gregory G, Gangatharan S, Hapgood G, Cochrane T, Cheah C, Gibbs S, Wei A, Johnston A, Greenwood M, Prince HM, Latimer M, Berkahn L, Wight J, Armytage T, Hamad N. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Intern Med J 2021;51:763-8. [PMID: 34047035 DOI: 10.1111/imj.15247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, Papanagnou ED, Fotiou D, Kastritis E, Dimopoulos MA. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood 2021;137:3674-6. [PMID: 33861315 DOI: 10.1182/blood.2021011904] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 27.0] [Reference Citation Analysis]
23 Greenberg RS, Ruddy JA, Boyarsky BJ, Werbel WA, Garonzik-Wang JM, Segev DL, Imus PH. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma. BMC Cancer 2021;21:1354. [PMID: 34961488 DOI: 10.1186/s12885-021-09097-5] [Reference Citation Analysis]
24 Piñana JL, Vázquez L, Martino R, de la Cámara R, Sureda A, Rodríguez-Veiga R, Garrido A, Sierra J, Ribera JM, Torrent A, Mateos MV, de la Rubia J, Tormo M, Díez-Campelo M, García-Gutiérrez V, Álvarez-Larrán A, Sancho JM, MartínGarcía-Sancho A, Yañez L, Pérez Simón JA, Barba P, Abrisqueta P, Álvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernández-Rivas JÁ, Cedillo Á, García-Sanz R, Bosch F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leuk Lymphoma 2021;:1-13. [PMID: 34668835 DOI: 10.1080/10428194.2021.1992619] [Reference Citation Analysis]
25 Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. [PMID: 34653748 DOI: 10.1016/j.ctarc.2021.100476] [Reference Citation Analysis]
26 Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Preugschat K, Feinstein AJ, Spektor TM, Berenson JR. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia 2021. [PMID: 34326466 DOI: 10.1038/s41375-021-01354-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 See KC. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines 2022;10:800. [DOI: 10.3390/vaccines10050800] [Reference Citation Analysis]
28 Chicca IJ, Heaney JLJ, Iqbal G, Dunn JA, Bowcock S, Pratt G, Yong KL, Planche TD, Richter A, Drayson MT. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. Blood Cancer J 2020;10:114. [PMID: 33149136 DOI: 10.1038/s41408-020-00370-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Schiller Salton N, Szwarcwort M, Tzoran I, Horowitz NA, Zuckerman T, Horesh N, Shachor-Meyouhas Y, Hussein K, Lavi N. Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis. Am J Hematol 2021;96:E475-8. [PMID: 34622495 DOI: 10.1002/ajh.26373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. Hemasphere 2021;5:e547. [PMID: 33623886 DOI: 10.1097/HS9.0000000000000547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
31 Chan WY, Sanchez E, Chavda SJ, Lecat CSY, Ainley L, Xu K, Wisniowski B, Mahmood S, Papanikolaou X, Kyriakou C, Sive J, Wechalekar A, Popat R, Rabin N, Lee L, Nastouli E, Yong KL. Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. Br J Haematol 2021;194:857-61. [PMID: 34323287 DOI: 10.1111/bjh.17441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Wu AHB, Wang CC, Ong CM, Lynch KL. Adequate Antibody Response to COVID-19 Vaccine in Patients with Monoclonal Gammopathies and Light Chain Amyloidosis. Lab Med 2022:lmab113. [PMID: 35026018 DOI: 10.1093/labmed/lmab113] [Reference Citation Analysis]
33 Radocha J, van de Donk NWCJ, Weisel K. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers (Basel) 2021;13:1571. [PMID: 33805481 DOI: 10.3390/cancers13071571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]